Details: pack, label wording, sources, registration
Adep 30 mg, Tablet
film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause
5.9/10
Weak evidence support
Details →
30 mg, film-coated tablet, human medicine
Assessed clinical scope Dog · Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause · oral
Care setting Veterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score
5.9/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-041752 · Verified on 16 Oct 2026
Off-label use
Oral mirtazapine has current evidence as a short-term second-line appetite stimulant in selected dogs, but this whole-only 30 mg human tablet is poorly scaled to many patients. Diagnose and treat the cause of hyporexia, use a validated patient-specific dose, review serotonergic combinations and escalate to assisted nutrition when intake remains inadequate.
Regulatory and scientific credibility 5.5/10
The exact human 30 mg tablet is currently registered in Georgia, but no exact EU/EEA, GB or US registration and no veterinary authorisation were found in the checked registers. Oral species evidence supports mirtazapine as an ingredient, not the dose accuracy or veterinary suitability of this exact whole-only presentation.
Clinical efficacy 6.5/10
A 2025 study combined 107 retrospective clinical cases with a 25-dog placebo-controlled crossover trial: mirtazapine improved voluntary food acceptance on day 1 and was associated with less weight loss, but the prospective advantage was not maintained on day 2. This supports a useful short-term second-line role, not replacement of diagnosis, anti-nausea treatment or assisted enteral nutrition.
Safety and tolerability 6.0/10
The current placebo-controlled study reported no short-term adverse effects, but canine safety numbers remain modest. Sedation or excitation, gastrointestinal signs, cardiovascular change and serotonin toxicity are plausible; human labelling and class pharmacology require review of serotonergic drugs, monoamine-oxidase inhibitors, organ disease and repeated exposure.
Clinical practicality 5.5/10
A 30 mg whole-only tablet can match some very large dogs but is poorly scaled to many canine doses. Crushing may permit pharmacy compounding, but informal powder division or guessed fragments do not establish content uniformity; use a validated patient-specific preparation rather than improvised fractions.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration. The 30 mg tablet is whole-only in the catalogue and is too large for many canine regimens. Do not assume that crushing makes home division accurate; use a pharmacy-validated patient-specific preparation when the prescribed dose is not a whole tablet. Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures. Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity. Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule. Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable. An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition. Assessment sources +
Close
Cat
Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause
5.8/10
Weak evidence support
Details →
30 mg, film-coated tablet, human medicine
Assessed clinical scope Cat · Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause · oral
Care setting Veterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score
5.8/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-041752 · Verified on 16 Oct 2026
Off-label use
Oral mirtazapine can improve appetite and weight and reduce vomiting in selected cats, especially those with stable CKD, but this whole-only 30 mg tablet is an unsafe practical match to the approximately 1.88-2 mg studied dose. Prefer an authorised feline formulation or an accurately prepared low-dose product and adjust monitoring for renal or hepatic disease.
Regulatory and scientific credibility 5.5/10
The exact human 30 mg tablet is currently registered in Georgia, but no exact EU/EEA, GB or US registration and no veterinary authorisation were found in the checked registers. Oral species evidence supports mirtazapine as an ingredient, not the dose accuracy or veterinary suitability of this exact whole-only presentation.
Clinical efficacy 7.5/10
A masked placebo-controlled crossover trial in 11 cats with stable CKD found improved appetite and activity, reduced vomiting and median weight gain of 0.18 kg over three weeks; healthy-cat pharmacodynamic work also showed increased intake. Samples are small and do not establish equal benefit in every cause of feline hyporexia, but oral efficacy is clinically credible.
Safety and tolerability 6.5/10
Feline oral studies define common behavioural and gastrointestinal effects and show slower clearance in renal and especially hepatic disease. An 84-case toxicosis series found vocalisation, agitation, vomiting, ataxia, tremor, tachypnoea and tachycardia, commonly after 15 mg accidental ingestion; an accurately measured low dose is therefore central to safety.
Clinical practicality 2.0/10
The studied oral feline dose is about 1.88-2 mg, roughly one sixteenth of this 30 mg whole-only tablet. That dose cannot be delivered accurately by ordinary splitting, and accidental administration of 15-30 mg is a documented toxicosis pattern. A licensed feline product or validated low-dose compounded preparation is far more practical.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration. This whole-only 30 mg tablet cannot accurately deliver the approximately 1.88-2 mg oral dose studied in cats. Do not estimate one-sixteenth fragments or dispense loose hand-divided powder; use an authorised feline product or a pharmacy-validated low-dose preparation. Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures. Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity. Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule. Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable. An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Yes, human
In force until 01 Aug 2029
Human (Ministry of Health, RAMA)
In the register: ადეპი 30 მგ, აბი
№ რ-041752
Verified on: 16 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
